RNAi Technology - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510244754

Publication Date:

October 29, 2024

Pages:

110

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

RNA interference is a relatively new concept in the field of medicine. It is a process in which the ribonucleic acid inhibits translation or gene expression by converting single-stranded mRNA to double stranded RNA, thereby neutralizing the target nucleic acids.
The global market for RNAi Technology was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
As an important force driving a new round of scientific and technological revolution, artificial intelligence has been of national strategic importance. Many governments introduces polices and increase capital investment to support AI companies. The Digital Europe plan adopted by the European Union will allocate 鈧�9.2 billion on high-tech investments, such as supercomputing, artificial intelligence, and network security. In order to maintain its leading position, the United States will increase its investment in artificial intelligence research and development in non-defense fields, from US$1.6 billion to US$1.7 billion in 2022. According to the latest data released by IDC, global artificial intelligence revenue was US$432.8 billion in 2022, a year-on-year increase of 19.97%, including software, hardware and services.
Report Scope
This report aims to provide a comprehensive presentation of the global market for RNAi Technology, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of RNAi Technology by region & country, by Type, and by Application.
The RNAi Technology market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNAi Technology.
Market Segmentation
By Company
Alnylam Pharmaceuticals
Dicerna Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc.
Arbutus Biopharma
Benitec Biopharma
Calando
Silence Therapeutics
Gotham Therapeutics
Segment by Type:
Cancer
Liver Disorders
Respiratory Disorders
Neurological Disorders
Autoimmune Disorders
Others
Segment by Application
Drug Discovery & Development
Therapeutics
Drug Delivery
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of RNAi Technology manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of RNAi Technology in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of RNAi Technology in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 RNAi Technology Product Introduction
1.2 Global RNAi Technology Market Size Forecast
1.3 RNAi Technology Market Trends & Drivers
1.3.1 RNAi Technology Industry Trends
1.3.2 RNAi Technology Market Drivers & Opportunity
1.3.3 RNAi Technology Market Challenges
1.3.4 RNAi Technology Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global RNAi Technology Players Revenue Ranking (2023)
2.2 Global RNAi Technology Revenue by Company (2019-2024)
2.3 Key Companies RNAi Technology Manufacturing Base Distribution and Headquarters
2.4 Key Companies RNAi Technology Product Offered
2.5 Key Companies Time to Begin Mass Production of RNAi Technology
2.6 RNAi Technology Market Competitive Analysis
2.6.1 RNAi Technology Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by RNAi Technology Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi Technology as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Cancer
3.1.2 Liver Disorders
3.1.3 Respiratory Disorders
3.1.4 Neurological Disorders
3.1.5 Autoimmune Disorders
3.1.6 Others
3.2 Global RNAi Technology Sales Value by Type
3.2.1 Global RNAi Technology Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global RNAi Technology Sales Value, by Type (2019-2030)
3.2.3 Global RNAi Technology Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Drug Discovery & Development
4.1.2 Therapeutics
4.1.3 Drug Delivery
4.1.4 Others
4.2 Global RNAi Technology Sales Value by Application
4.2.1 Global RNAi Technology Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global RNAi Technology Sales Value, by Application (2019-2030)
4.2.3 Global RNAi Technology Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global RNAi Technology Sales Value by Region
5.1.1 Global RNAi Technology Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global RNAi Technology Sales Value by Region (2019-2024)
5.1.3 Global RNAi Technology Sales Value by Region (2025-2030)
5.1.4 Global RNAi Technology Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America RNAi Technology Sales Value, 2019-2030
5.2.2 North America RNAi Technology Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe RNAi Technology Sales Value, 2019-2030
5.3.2 Europe RNAi Technology Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific RNAi Technology Sales Value, 2019-2030
5.4.2 Asia Pacific RNAi Technology Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America RNAi Technology Sales Value, 2019-2030
5.5.2 South America RNAi Technology Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa RNAi Technology Sales Value, 2019-2030
5.6.2 Middle East & Africa RNAi Technology Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions RNAi Technology Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions RNAi Technology Sales Value
6.3 United States
6.3.1 United States RNAi Technology Sales Value, 2019-2030
6.3.2 United States RNAi Technology Sales Value by Type (%), 2023 VS 2030
6.3.3 United States RNAi Technology Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe RNAi Technology Sales Value, 2019-2030
6.4.2 Europe RNAi Technology Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe RNAi Technology Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China RNAi Technology Sales Value, 2019-2030
6.5.2 China RNAi Technology Sales Value by Type (%), 2023 VS 2030
6.5.3 China RNAi Technology Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan RNAi Technology Sales Value, 2019-2030
6.6.2 Japan RNAi Technology Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan RNAi Technology Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea RNAi Technology Sales Value, 2019-2030
6.7.2 South Korea RNAi Technology Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea RNAi Technology Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia RNAi Technology Sales Value, 2019-2030
6.8.2 Southeast Asia RNAi Technology Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia RNAi Technology Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India RNAi Technology Sales Value, 2019-2030
6.9.2 India RNAi Technology Sales Value by Type (%), 2023 VS 2030
6.9.3 India RNAi Technology Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Alnylam Pharmaceuticals
7.1.1 Alnylam Pharmaceuticals Profile
7.1.2 Alnylam Pharmaceuticals Main Business
7.1.3 Alnylam Pharmaceuticals RNAi Technology Products, Services and Solutions
7.1.4 Alnylam Pharmaceuticals RNAi Technology Revenue (US$ Million) & (2019-2024)
7.1.5 Alnylam Pharmaceuticals Recent Developments
7.2 Dicerna Pharmaceuticals, Inc.
7.2.1 Dicerna Pharmaceuticals, Inc. Profile
7.2.2 Dicerna Pharmaceuticals, Inc. Main Business
7.2.3 Dicerna Pharmaceuticals, Inc. RNAi Technology Products, Services and Solutions
7.2.4 Dicerna Pharmaceuticals, Inc. RNAi Technology Revenue (US$ Million) & (2019-2024)
7.2.5 Dicerna Pharmaceuticals, Inc. Recent Developments
7.3 Arrowhead Pharmaceuticals, Inc.
7.3.1 Arrowhead Pharmaceuticals, Inc. Profile
7.3.2 Arrowhead Pharmaceuticals, Inc. Main Business
7.3.3 Arrowhead Pharmaceuticals, Inc. RNAi Technology Products, Services and Solutions
7.3.4 Arrowhead Pharmaceuticals, Inc. RNAi Technology Revenue (US$ Million) & (2019-2024)
7.3.5 Ionis Pharmaceuticals, Inc. Recent Developments
7.4 Ionis Pharmaceuticals, Inc.
7.4.1 Ionis Pharmaceuticals, Inc. Profile
7.4.2 Ionis Pharmaceuticals, Inc. Main Business
7.4.3 Ionis Pharmaceuticals, Inc. RNAi Technology Products, Services and Solutions
7.4.4 Ionis Pharmaceuticals, Inc. RNAi Technology Revenue (US$ Million) & (2019-2024)
7.4.5 Ionis Pharmaceuticals, Inc. Recent Developments
7.5 Quark Pharmaceuticals, Inc.
7.5.1 Quark Pharmaceuticals, Inc. Profile
7.5.2 Quark Pharmaceuticals, Inc. Main Business
7.5.3 Quark Pharmaceuticals, Inc. RNAi Technology Products, Services and Solutions
7.5.4 Quark Pharmaceuticals, Inc. RNAi Technology Revenue (US$ Million) & (2019-2024)
7.5.5 Quark Pharmaceuticals, Inc. Recent Developments
7.6 Arbutus Biopharma
7.6.1 Arbutus Biopharma Profile
7.6.2 Arbutus Biopharma Main Business
7.6.3 Arbutus Biopharma RNAi Technology Products, Services and Solutions
7.6.4 Arbutus Biopharma RNAi Technology Revenue (US$ Million) & (2019-2024)
7.6.5 Arbutus Biopharma Recent Developments
7.7 Benitec Biopharma
7.7.1 Benitec Biopharma Profile
7.7.2 Benitec Biopharma Main Business
7.7.3 Benitec Biopharma RNAi Technology Products, Services and Solutions
7.7.4 Benitec Biopharma RNAi Technology Revenue (US$ Million) & (2019-2024)
7.7.5 Benitec Biopharma Recent Developments
7.8 Calando
7.8.1 Calando Profile
7.8.2 Calando Main Business
7.8.3 Calando RNAi Technology Products, Services and Solutions
7.8.4 Calando RNAi Technology Revenue (US$ Million) & (2019-2024)
7.8.5 Calando Recent Developments
7.9 Silence Therapeutics
7.9.1 Silence Therapeutics Profile
7.9.2 Silence Therapeutics Main Business
7.9.3 Silence Therapeutics RNAi Technology Products, Services and Solutions
7.9.4 Silence Therapeutics RNAi Technology Revenue (US$ Million) & (2019-2024)
7.9.5 Silence Therapeutics Recent Developments
7.10 Gotham Therapeutics
7.10.1 Gotham Therapeutics Profile
7.10.2 Gotham Therapeutics Main Business
7.10.3 Gotham Therapeutics RNAi Technology Products, Services and Solutions
7.10.4 Gotham Therapeutics RNAi Technology Revenue (US$ Million) & (2019-2024)
7.10.5 Gotham Therapeutics Recent Developments
8 Industry Chain Analysis
8.1 RNAi Technology Industrial Chain
8.2 RNAi Technology Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 RNAi Technology Sales Model
8.5.2 Sales Channel
8.5.3 RNAi Technology Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Alnylam Pharmaceuticals
Dicerna Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc.
Arbutus Biopharma
Benitec Biopharma
Calando
Silence Therapeutics
Gotham Therapeutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂